Immunocore Holdings (IMCR) Stock Forecast & Price Target

Compare

238 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMCR Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Immunocore

Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMCR Stock 12 Month Forecast

Average Price Target

$65.25

▲(81.15% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Immunocore Holdings in the last 3 months. The average price target is $65.25 with a high forecast of $100.00 and a low forecast of $36.00. The average price target represents a 81.15% change from the last price of $36.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","64":"$64","101":"$101","45.5":"$45.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$65.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,45.5,64,82.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.59,42.39076923076924,47.191538461538464,51.99230769230769,56.793076923076924,61.59384615384616,66.39461538461538,71.19538461538461,75.99615384615385,80.79692307692308,85.59769230769231,90.39846153846153,95.19923076923077,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.59,39.71769230769231,41.84538461538462,43.973076923076924,46.10076923076923,48.22846153846154,50.356153846153845,52.48384615384616,54.61153846153846,56.73923076923077,58.86692307692307,60.994615384615386,63.12230769230769,{"y":65.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.59,37.46769230769231,37.34538461538462,37.223076923076924,37.10076923076923,36.97846153846154,36.856153846153845,36.73384615384616,36.611538461538466,36.48923076923077,36.36692307692308,36.244615384615386,36.12230769230769,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$65.25

Lowest Price Target$36.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$100

Buy

177.62%

Upside

Reiterated

12/12/25

Immunocore Holdings (IMCR) Receives a Rating Update from a Top Analyst

Tyler Van Buren

TD Cowen

$60

Buy

66.57%

Upside

Reiterated

11/13/25

Immunocore's Strong Growth Potential Justifies Buy Rating Despite Minor Revenue Adjustment

Graig Suvannavejh

Mizuho Securities

$36→$37

Hold

2.72%

Upside

Reiterated

11/10/25

Immunocore Holdings (IMCR) Gets a Hold from Mizuho Securitieswe stay Neutral on IMCR

Sean Laaman

Morgan Stanley

$34→$36

Hold

-0.06%

Downside

Reiterated

11/10/25

Immunocore price target raised to $36 from $34 at Morgan StanleyImmunocore price target raised to $36 from $34 at Morgan Stanley

Jeff Jones

Oppenheimer

$86

Buy

138.76%

Upside

Reiterated

11/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Rajan Sharma

Goldman Sachs

$71→$72

Buy

99.89%

Upside

Reiterated

11/07/25

Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), Immunocore Holdings (IMCR)

Gil Blum

Needham

$71

Buy

97.11%

Upside

Reiterated

11/06/25

Immunocore Holdings (IMCR) Receives a Buy from NeedhamWe maintain our Buy Rating and $71 Target.

Eva Fortea Verdejo

Wells Fargo

$60

Buy

66.57%

Upside

Initiated

10/31/25

Immunocore initiated with an Overweight at Wells FargoImmunocore initiated with an Overweight at Wells Fargo

Paul Jeng

Guggenheim

―

Hold

―

Initiated

09/17/25

Immunocore assumed with a Neutral at GuggenheimImmunocore assumed with a Neutral at Guggenheim

Kelly Shi

Jefferies

$48

Buy

33.26%

Upside

Initiated

08/24/25

Immunocore Holdings (IMCR) Receives a New Rating from Jefferies

Jonathan Chang

Leerink Partners

$67→$60

Buy

66.57%

Upside

Reiterated

08/11/25

Leerink Partners Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)

Peter Lawson

Barclays

$52

Buy

44.36%

Upside

Reiterated

08/08/25

Barclays Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)

James Shin

Deutsche Bank

$65

Buy

80.46%

Upside

Initiated

05/27/25

Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank

Jessica Fye

J.P. Morgan

$50

Buy

38.81%

Upside

Reiterated

04/11/25

J.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)

Justin Zelin

BTIG

$91

Buy

152.64%

Upside

Reiterated

03/11/25

BTIG reiterates Buy Rating on Immunocore Holdings (IMCR), PT $91BTIG analyst Justin Zelin reiterated a Buy rating and $91.00 price target on Immunocore Holdings (NASDAQ: IMCR)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$100

Buy

177.62%

Upside

Reiterated

12/12/25

Immunocore Holdings (IMCR) Receives a Rating Update from a Top Analyst

Tyler Van Buren

TD Cowen

$60

Buy

66.57%

Upside

Reiterated

11/13/25

Immunocore's Strong Growth Potential Justifies Buy Rating Despite Minor Revenue Adjustment

Graig Suvannavejh

Mizuho Securities

$36→$37

Hold

2.72%

Upside

Reiterated

11/10/25

Immunocore Holdings (IMCR) Gets a Hold from Mizuho Securitieswe stay Neutral on IMCR

Sean Laaman

Morgan Stanley

$34→$36

Hold

-0.06%

Downside

Reiterated

11/10/25

Immunocore price target raised to $36 from $34 at Morgan StanleyImmunocore price target raised to $36 from $34 at Morgan Stanley

Jeff Jones

Oppenheimer

$86

Buy

138.76%

Upside

Reiterated

11/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Rajan Sharma

Goldman Sachs

$71→$72

Buy

99.89%

Upside

Reiterated

11/07/25

Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), Immunocore Holdings (IMCR)

Gil Blum

Needham

$71

Buy

97.11%

Upside

Reiterated

11/06/25

Immunocore Holdings (IMCR) Receives a Buy from NeedhamWe maintain our Buy Rating and $71 Target.

Eva Fortea Verdejo

Wells Fargo

$60

Buy

66.57%

Upside

Initiated

10/31/25

Immunocore initiated with an Overweight at Wells FargoImmunocore initiated with an Overweight at Wells Fargo

Paul Jeng

Guggenheim

―

Hold

―

Initiated

09/17/25

Immunocore assumed with a Neutral at GuggenheimImmunocore assumed with a Neutral at Guggenheim

Kelly Shi

Jefferies

$48

Buy

33.26%

Upside

Initiated

08/24/25

Immunocore Holdings (IMCR) Receives a New Rating from Jefferies

Jonathan Chang

Leerink Partners

$67→$60

Buy

66.57%

Upside

Reiterated

08/11/25

Leerink Partners Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)

Peter Lawson

Barclays

$52

Buy

44.36%

Upside

Reiterated

08/08/25

Barclays Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)

James Shin

Deutsche Bank

$65

Buy

80.46%

Upside

Initiated

05/27/25

Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank

Jessica Fye

J.P. Morgan

$50

Buy

38.81%

Upside

Reiterated

04/11/25

J.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)

Justin Zelin

BTIG

$91

Buy

152.64%

Upside

Reiterated

03/11/25

BTIG reiterates Buy Rating on Immunocore Holdings (IMCR), PT $91BTIG analyst Justin Zelin reiterated a Buy rating and $91.00 price target on Immunocore Holdings (NASDAQ: IMCR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunocore Holdings

1 Month

xxx

Success Rate

10/23 ratings generated profit

Average Return

-1.37%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.48% of your transactions generating a profit, with an average return of -1.37% per trade.

3 Months

xxx

Success Rate

12/23 ratings generated profit

Average Return

+1.50%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +1.50% per trade.

1 Year

Jessica FyeJ.P. Morgan

Success Rate

7/13 ratings generated profit

Average Return

+11.92%

reiterated a buy rating 8 months ago

Copying Jessica Fye's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +11.92% per trade.

2 Years

xxx

Success Rate

9/16 ratings generated profit

Average Return

-3.94%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of -3.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMCR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMCR has received 11 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. IMCR average Analyst price target in the past 3 months is 65.25.

Each month's total comprises the sum of three months' worth of ratings.

IMCR Financial Forecast

IMCR Earnings Forecast

Next quarter’s earnings estimate for IMCR is -$0.19 with a range of -$0.77 to $0.17. The previous quarter’s EPS was $0.00. IMCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Sales Forecast

Next quarter’s sales forecast for IMCR is $107.75M with a range of $102.70M to $112.97M. The previous quarter’s sales results were $103.07M. IMCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Stock Forecast FAQ

What is IMCR’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunocore Holdings’s 12-month average price target is 65.25.

What is IMCR’s upside potential, based on the analysts’ average price target?

Immunocore Holdings has 81.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMCR a Buy, Sell or Hold?

Immunocore Holdings has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Immunocore Holdings’s price target?

The average price target for Immunocore Holdings is 65.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $36.00. The average price target represents 81.15% Increase from the current price of $36.02.

What do analysts say about Immunocore Holdings?

Immunocore Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of IMCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Immunocore Holdings (IMCR) Stock Forecast & Price Target

IMCR Analyst Ratings

IMCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunocore Holdings

IMCR Analyst Recommendation Trends

IMCR Financial Forecast

IMCR Earnings Forecast

IMCR Sales Forecast

IMCR Stock Forecast FAQ

Detailed List of Analyst Forecasts